The US Food and Drug Administration (FDA) authorized the intradermal injection of monkeypox vaccines in adults, in an attempt to manage low vaccine supply versus rising demand for vaccines, on Tuesday, 10 August.
Intradermal injections are administered between the layers of skin rather than under the skin, and are expected to cut vaccine requirements to 1/5th of the present need.
While no dedicated vaccine exists currently for monkeypox, repurposed smallpox vaccines have been approved for use in many countries including the US, Australia, the UK, the European Union, and Singapore.